Trial Profile

A Case Series Follow-up of 15 Patients Living with Autoimmune Disease Treated With CAR T-Cell Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mivocabtagene autoleucel (Primary)
Indications Autoimmune disorders; Myositis; Systemic lupus erythematosus; Systemic scleroderma
Focus Adverse reactions; Therapeutic Use
Acronyms KYSA-6

Most Recent Events

26 Mar 2026 According to a Kyverna Therapeutics media release, additional longer-term follow-up Phase 2 data will be shared in an oral presentation at AAN on April 20, 2026.
13 Jan 2026 According to a Kyverna Therapeutics media release, Company expects to report updated Phase 2 data from the gMG trial in 2026.
29 Feb 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com